{'fraction_non_alphanumeric': 0.018641810918774968, 'fraction_numerical': 0.002663115845539281, 'mean_word_length': 6.02803738317757, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Metformin Inhibits Cyst Growth and Alters Cell Metabolism in Vitro and Improves Relevant Disease Parameters in a Hypomorphic ADPKD Mouse Model

Autosomal dominant polycystic kidney disease (ADPKD), caused by mutations in the Pkd1 or Pkd2 genes encoding polycystins, presents with progressive development of renal cysts and eventual end‐stage kidney disease and has limited treatment options. Previous work showed that metformin treatment reduces cyst growth in early, rapid ADPKD mouse models, potentially through AMPK‐dependent inhibition of CFTR‐mediated fluid secretion, mTOR signaling and cAMP production. Here we tested whether metformin treatment ameliorated ADPKD manifestations in vitro and in a relevant, slowly progressive ADPKD mouse model.